Vendor, Morrisville, NC
Inhalon Biopharma, Inc.
UEI HFQSJ2GMNRU6, CAGE 87U21
2 awards and $5,410,293 obligated between September 16, 2024 and September 22, 2025, 100% under full and open competition, against 45.5 offers on average where reported.
Industries
NAICS on the awards, by dollars.
| Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)NAICS 541715 | $5,410,293 |
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition | 2 |
| Definitive Contract | 2 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| HT942525CE039Definitive Contract, September 22, 2025, Full and Open Competition, 44 offers | Army Med Res Acq ActivityDefense Health Agency | A Phase 1 Placebo-Controlled Dose-Escalation Safety and Pharmacokinetic Study of IN-007, a Nebulized, PAN-SARS Ace2-Decoy Therapeutic for PaNAICS 541715, PSC AN13 | $3,175,643 |
| HT942524C0076Definitive Contract, September 16, 2024, Full and Open Competition, 47 offers | Army Med Res Acq ActivityDefense Health Agency | Developing IN-007 as a Widely Deployable Inhaled Treatment Against Pathogens Utilizing Human ACE2 for Viral Attachment and EntryNAICS 541715, PSC AN12 | $2,234,650 |
- Places of performance
- North Carolina
- Product and service codes
- AN13 Health R&D Services; Health Care Services; Experimental DevelopmentAN12 Health R&D Services; Health Care Services; Applied Research
- Transactions
- 4 across 2 awards